SAN DIEGO, Sept. 18, 2018 /PRNewswire/ -- Trovagene, Inc.
(NASDAQ: TROV), a clinical-stage oncology therapeutics
company, developing targeted therapies for the treatment of
leukemias, lymphomas and solid tumor cancers, today announced it
will be featured as a presenting company at The MicroCap Conference
that is being held on October
1st and 2nd, 2018 at the Essex House
in New York City.
Dr. Thomas Adams, Executive
Chairman of Trovagene, Inc., will provide an overview of the
Company, the current status of ongoing clinical trials in Acute
Myeloid Leukemia (AML) and metastatic Castration-Resistant Prostate
Cancer (mCRPC), as well as anticipated near-term milestones, during
the live presentation on October
2nd at 10:30 AM eastern
time. Dr. Adams and Dr. Mark
Erlander, Chief Scientific Officer, will also be available
to participate in one-on-one meetings with investors who are
registered to attend the conference, on Monday, October 1st and Tuesday, October 2nd.
If you are an investor, and would like to attend the Company's
presentation, please click on the following link
(www.microcapconf.com) to register for the conference. Once
your registration is confirmed, you will be prompted to log into
the conference website to request a one-on-one meeting with
Trovagene.
Event: MicroCap
Conference
Trovagene Company Presentation
Date: October
2nd
Time: 10:30 – 11:00 AM (Eastern Time)
Location: Kensington (2nd Floor); the Essex
House in New York City
About Trovagene, Inc.
Trovagene is a clinical-stage, oncology therapeutics company,
using a precision medicine approach to develop drugs that target
mitosis (cell division) to treat various types of cancer, including
leukemias, lymphomas and solid tumors. Trovagene has intellectual
property and proprietary technology that enables the Company to
analyze circulating tumor DNA (ctDNA) and clinically actionable
markers to identify patients most likely to respond to specific
cancer therapies. Trovagene plans to continue to vertically
integrate its tumor genomics technology with the development of
targeted cancer therapeutics. For more information, please
visit https://www.trovagene.com
Forward-Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of words
such as "anticipate," "believe," "forecast," "estimated" and
"intend" or other similar terms or expressions that concern
Trovagene's expectations, strategy, plans or intentions. These
forward-looking statements are based on Trovagene's current
expectations and actual results could differ materially.
There are a number of factors that could cause actual events
to differ materially from those indicated by such forward-looking
statements. These factors include, but are not limited to,
our need for additional financing; our ability to continue as a
going concern; clinical trials involve a lengthy and expensive
process with an uncertain outcome, and results of earlier studies
and trials may not be predictive of future trial results; our
clinical trials may be suspended or discontinued due to unexpected
side effects or other safety risks that could preclude approval of
our product candidates; uncertainties of government or third party
payer reimbursement; dependence on key personnel; limited
experience in marketing and sales; substantial competition;
uncertainties of patent protection and litigation; dependence upon
third parties; our ability to develop tests, kits and systems and
the success of those products; regulatory, financial and business
risks related to our international expansion and risks related to
failure to obtain FDA clearances or approvals and noncompliance
with FDA regulations. There are no guarantees that any of our
technology or products will be utilized or prove to be commercially
successful, or that Trovagene's strategy to design its liquid
biopsy tests to report on clinically actionable cancer genes will
ultimately be successful or result in better reimbursement
outcomes. Additionally, there are no guarantees that future
clinical trials will be completed or successful or that any
precision medicine therapeutics will receive regulatory approval
for any indication or prove to be commercially successful.
Investors should read the risk factors set forth in Trovagene's
Form 10-K for the year ended December 31, 2017, and other
periodic reports filed with the Securities and Exchange
Commission. While the list of factors presented here is
considered representative, no such list should be considered to be
a complete statement of all potential risks and uncertainties.
Unlisted factors may present significant additional obstacles
to the realization of forward-looking statements.
Forward-looking statements included herein are made as of the
date hereof, and Trovagene does not undertake any obligation to
update publicly such statements to reflect subsequent events or
circumstances.
Trovagene Contact:
Vicki
Kelemen
VP, Corporate Communications
858-952-7652
vkelemen@trovagene.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/trovagene-announces-participation-at-the-microcap-conference-on-october-1st-and-2nd-at-the-essex-house-in-new-york-city-300714285.html
SOURCE Trovagene, Inc.